Drug Topics March 15, 2024
Killian Meara

The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, in which the CAR T cell therapy demonstrated statistically significant complete response rates.

Lisocabtagene maraleucel (Breyanzi; liso-cel) has received accelerated approval from the FDA for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have received at least 2 prior lines of therapy, Bristol Myers Squibb announced in a release.1

The approval was based on data from the phase 1/2 TRANSCEND CLL 004 (NCT03331198) study, in which lisocabtagene maraleucel demonstrated statistically significant complete response rates (CR) in a primary efficacy analysis, with no disease progression or deaths among the patients who achieved CR.

“CAR T...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
11 drugs now in shortage
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
FDA Launches ‘Home as a Health Care Hub’ Initiative With Equity Focus

Share This Article